KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Equity Average (2016 - 2026)

Emergent BioSolutions has reported Equity Average over the past 16 years, most recently at $522.8 million for Q1 2026.

  • For Q1 2026, Equity Average rose 0.99% year-over-year to $522.8 million; the TTM value through Mar 2026 reached $522.8 million, up 0.99%, while the annual FY2025 figure was $502.7 million, 11.19% down from the prior year.
  • Equity Average for Q1 2026 was $522.8 million at Emergent BioSolutions, down from $552.6 million in the prior quarter.
  • Over five years, Equity Average peaked at $1.6 billion in Q1 2022 and troughed at $447.4 million in Q3 2024.
  • A 5-year average of $865.1 million and a median of $656.6 million in 2024 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: crashed 52.26% in 2023 and later grew 25.04% in 2025.
  • Year by year, Equity Average stood at $1.4 billion in 2022, then plummeted by 52.26% to $673.2 million in 2023, then dropped by 26.39% to $495.6 million in 2024, then rose by 11.49% to $552.6 million in 2025, then fell by 5.38% to $522.8 million in 2026.
  • Business Quant data shows Equity Average for EBS at $522.8 million in Q1 2026, $552.6 million in Q4 2025, and $559.4 million in Q3 2025.